DaShenLin Pharmaceutical Group 大参林
12 significant filings since 29 May 2026: 2 on regulatory inquiry, 4 on dividend and 2 on guarantee or financial assistance, and 3 other kinds. The latest, on 25 Aug 2026: 大参林医药集团股份有限公司关于2026年半年度利润分配方案的公告.
自 29 May 2026 起有 12 份重大公告：regulatory inquiry 2 份、dividend 4 份、guarantee or financial assistance 2 份，另有 3 类。最新一份（25 Aug 2026）：大参林医药集团股份有限公司关于2026年半年度利润分配方案的公告。
Forecasts made more than 3 years before their fiscal year began, or after its results were filed, are excluded (1 of 70). 财年开始前 3 年以上或业绩披露后作出的预测不计入（70 份中 1 份）。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 1.31 | 1.50 |
| 7 days ago | 1.31 | 1.50 |
| 30 days ago | 1.30 | 1.50 |
| 60 days ago | 1.30 | 1.46 |
| 90 days ago | 1.30 | 1.46 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus moved from 1.22 in Dec 2024 to 1.31 in Sep 2026 (+7.0%). 一致预期从 Dec 2024 的 1.22 变为 Sep 2026 的 1.31 (+7.0%)。 The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 1 | ▲ 1 ▼ 0 = 0 |
| Last 90 days | ▲ 0 ▼ 0 = 4 | ▲ 1 ▼ 0 = 3 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
| Year | Filed | Consensus | Brokers 券商 | Reported 实际 | Surprise 偏差 |
|---|---|---|---|---|---|
| FY2022 | 28 Apr 2023 | 1.12 | 3 | 0.91 | -18.7% |
Surprise is reported EPS against the consensus on the day before the annual report was filed. 偏差为实际每股收益与年报披露前一日一致预期之差。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 1.